{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:26:42Z","timestamp":1767770802998,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013157","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000}}],"reference-count":407,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013157.pub2","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T16:02:41Z","timestamp":1626710561000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Oluyemi","family":"Komolafe","sequence":"additional","affiliation":[{"name":"University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Buzzetti","sequence":"additional","affiliation":[{"name":"Sheila Sherlock Liver Centre; Royal Free Hospital and the UCL Institute of Liver and Digestive Health; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Linden","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence MJ","family":"Best","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M","family":"Madden","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences; University of Hertfordshire; Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas JG","family":"Chase","sequence":"additional","affiliation":[{"name":"Department of General Surgery; Homerton University Hospital NHS Foundation Trust; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Fritche","sequence":"additional","affiliation":[{"name":"UCL Medical School; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne C","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; University of Leicester; Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola J","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; University of Leicester; Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex J","family":"Sutton","sequence":"additional","affiliation":[{"name":"Department of Health Sciences; University of Leicester; Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth Jane","family":"Milne","sequence":"additional","affiliation":[{"name":"Centre for Trust, Peace and Social Relations; Coventry University; Coventry UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Wright","sequence":"additional","affiliation":[{"name":"Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research; The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chavdar S","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Department of Therapy; I.M. Sechenov First Moscow State Medical University; Moscow Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian R","family":"Davidson","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science; University College London; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Tsochatzis","sequence":"additional","affiliation":[{"name":"Sheila Sherlock Liver Centre; Royal Free Hospital and the UCL Institute of Liver and Digestive Health; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurinchi Selvan","family":"Gurusamy","sequence":"additional","affiliation":[{"name":"Division of Surgery and Interventional Science; University College London; London UK"},{"name":"Department of Therapy; I.M. Sechenov First Moscow State Medical University; Moscow Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/hep.23239","article-title":"Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial","volume":"50","author":"Abdelmalek","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial","volume":"39","author":"Abhari","year":"2020","journal-title":"Clinical Nutrition ESPEN"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.sjbs.2020.04.037","article-title":"The effect of hydroalcoholic berberis integerrima fruits extract on the lipid profile, antioxidant parameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease","volume":"27","author":"Afsharinasab","year":"2020","journal-title":"Saudi Journal of Biological Sciences"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1-8","DOI":"10.5812\/hepatmon.102125","article-title":"Effect of beta vulgaris extract on liver enzymes in patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"20","author":"Afzali","year":"2020","journal-title":"Hepatitis Monthly"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S838","DOI":"10.1016\/S0168-8278(18)31953-6","article-title":"Change of microbiota in patients with improved fatty liver and obesity","volume":"68","author":"Ahn","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"355","key":"10.1002\/14651858.CD013157.pub2-BIB0006|cit6","first-page":"1771","article-title":"The effect of psyllium on anthropometric measurements and liver enzymes in overweight or obese adults with nonalcoholic fatty liver disease (NAFLD)","volume":"33","author":"Akbarzadeh","year":"2015","journal-title":"Journal of Isfahan Medical School"},{"issue":"112","key":"10.1002\/14651858.CD013157.pub2-BIB0007|cit7","first-page":"113","article-title":"The effect of microalgae chlorella vulgaris supplementation on inflammatory factors in non-alcoholic fatty liver disease: a double blind randomized clinical trial","volume":"24","author":"Aliashrafi","year":"2014","journal-title":"Journal of Mazandaran University of Medical Sciences"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0009|cit9","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"16","key":"10.1002\/14651858.CD013157.pub2-BIB0010|cit10","first-page":"3118","article-title":"Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study","volume":"19","author":"Aller","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.clnu.2017.05.028","article-title":"Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: a randomized, controlled trial","volume":"37","author":"Amanat","year":"2018","journal-title":"Clinical Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.clnu.2016.09.020","article-title":"Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: randomized, controlled, double-blind trial","volume":"36","author":"Amiri","year":"2017","journal-title":"Clinical Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0013|cit13","first-page":"71","article-title":"Effects of L-carnitine supplementation on body composition in patients with nonalcoholic steatohepatitis (NASH)","volume":"13","author":"Amiri-Moghadam","year":"2015","journal-title":"Current Topics in Nutraceutical Research"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e65925","DOI":"10.5812\/ircmj.65925","article-title":"The effect of alpha-lipoic acid on liver function and metabolic markers in obese patients with non-alcoholic fatty liver disease: a double-blind randomized controlled trial","volume":"20","author":"Amirkhizi","year":"2018","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"e67615","DOI":"10.5812\/ircmj.67615","article-title":"Effects of alpha-lipoic acid supplementation on oxidative stress status in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial","volume":"20","author":"Amirkhizi","year":"2018","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.15171\/apb.2018.036","article-title":"Effects of pharmacologic dose of resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asghari","year":"2018","journal-title":"Advanced Pharmaceutical Bulletin"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"International Journal of Preventive Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e42902","DOI":"10.5812\/ircmj.42902","article-title":"The effect of synbiotic supplementation on body composition and lipid profile in patients with NAFLD: a randomized, double blind, placebo-controlled clinical trial study","volume":"19","author":"Asgharian","year":"2017","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/S0168-8278(17)31216-3","article-title":"An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis patients","volume":"66","author":"Ashraf","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nutres.2013.11.005","article-title":"Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients","volume":"34","author":"Askari","year":"2014","journal-title":"Nutrition Research"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/ijp.IJP_17_19","article-title":"Comparison of the efficacy of oral fenugreek seeds hydroalcoholic extract versus placebo in nonalcoholic fatty liver disease; a randomized, triple-blind controlled pilot clinical trial","volume":"52","author":"Babaei","year":"2020","journal-title":"Indian Journal of Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/dc14-2852","article-title":"Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes (corona): a randomized controlled trial","volume":"38","author":"Bae","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.ctim.2020.102452","article-title":"The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial","volume":"52","author":"Bahrami","year":"2020","journal-title":"Complementary Therapies in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jn\/nxy088","article-title":"Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial","volume":"148","author":"Bakhshimoghaddam","year":"2018","journal-title":"Journal of Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0026|cit26","first-page":"S312","article-title":"Role of vitamin E and vitamin C for the treatment of nonalcoholic steatohepatitis in non-diabetic patients","volume":"14","author":"Barbakadze","year":"2020","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12916-016-0638-y","article-title":"No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Barchetta","year":"2016","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0028|cit28","unstructured":"Randomized double-blind intervention trial to assess the efficacy of vitamin D3 supplementation vs placebo in reducing hepatic steato-inflammation and cardio-metabolic risk profile in patients affected by type 2 diabetes and non-alcoholic fatty liver disease (NAFLD\/NASH) www.clinicaltrialsregister.eu\/ctr-search\/search?query=2011-003010-17"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"A204","DOI":"10.1136\/gutjnl-2012-302514c.50","article-title":"Effect of vitamin E and alfa lipoic acid (ALA) in non-alcoholic fatty liver disease: a randomised placebo control open label prospective clinical trial: VAIN trial","volume":"61","author":"Basu","year":"2012","journal-title":"Gut"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.14309\/00000434-201110002-00346","article-title":"Effect of vitamin E and alfa lipoic acid (ALA) in non alcoholic fatty liver disease: a randomized placebo control open label prospective clinical trial - VAIN trial","volume":"106","author":"Basu","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD013157.pub2-BIB0031|cit31","first-page":"1145a","article-title":"Effect of vitamin E and alfa lipoic acid (ALA) in non alcoholic fatty liver disease: a randomized placebo control open label prospective clinical trial - VAIN trial","volume":"54","author":"Basu","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jceh.2013.03.054","article-title":"Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non-alcoholic fatty liver disease - a randomized open label placebo controlled clinical prospective trial (captive)","volume":"3","author":"Basu","year":"2013","journal-title":"Journal of Clinical and Experimental Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1136\/gutjnl-2013-304907.052","article-title":"Curcumin, anti-oxidant, and pioglitazone therapy with inclusion of vitamin E in non alcoholic fatty liver disease - a randomized open label placebo controlled clinical prospective trial (captive)","volume":"62","author":"Basu","year":"2013","journal-title":"Gut"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"Journal of Food Science"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East Journal of Digestive Diseases"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0036|cit36","first-page":"19","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"19","author":"Bomhof","year":"2018","journal-title":"European Journal of Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0037|cit37","first-page":"15","article-title":"The efficacy of Eurosil 85-vit. E complex on metabolic profile in adults with non alcoholic fatty liver disease (NAFLD). A double-blind randomized placebo-controlled clinical study","volume":"45","author":"Bonfrate","year":"2015","journal-title":"European Journal of Clinical Investigation"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0038|cit38","first-page":"542a","article-title":"Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients","volume":"63","author":"Boonyagard","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"12 Suppl 8","key":"10.1002\/14651858.CD013157.pub2-BIB0039|cit39","first-page":"A105","article-title":"Impact of vitamin D replacement on liver enzymes in non-alcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial","volume":"103","author":"Boonyagard","year":"2020","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4274\/jcrpe.1749","article-title":"Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease","volume":"7","author":"Boyraz","year":"2015","journal-title":"Journal of Clinical Research in Pediatric Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0042|cit42","first-page":"A328","article-title":"Role of vitamin E for the treatment of nonalcoholic steatohepatitis (NASH) in patients with t2dm-a randomized, controlled trial","volume":"67","author":"Bril","year":"2018","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0043|cit43","first-page":"a468","article-title":"Benefits of docosahexanoic acid tissue enrichment in nonalcoholic fatty liver disease: results from a randomised, double-blind, placebo-controlled study testing the effects of omega-3 fatty acid treatment","volume":"63","author":"Byrne","year":"2014","journal-title":"Diabetes"},{"issue":"32","key":"10.1002\/14651858.CD013157.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"e21464","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0045|cit45","first-page":"75","article-title":"Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease - 14 months follow-up","volume":"65","author":"Celinski","year":"2014","journal-title":"Journal of Physiology and Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1017\/S0007114519002484","article-title":"Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease","volume":"123","author":"Cerletti","year":"2020","journal-title":"British Journal of Nutrition"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0048|cit48","first-page":"324","article-title":"Silymarin for the treatment of non-alcoholic steatohepatitis: interim analysis of a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Chan","year":"2015","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0168-8278(16)00204-X","article-title":"Silymarin improves fibrosis in non-alcoholic steatohepatitis","volume":"64","author":"Chan","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Chan","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S0168-8278(15)30166-5","article-title":"Silymarin for the treatment of non-alcoholic steatohepatitis: interim analysis of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Chan","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10620-006-8030-y","article-title":"Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study","volume":"51","author":"Chande","year":"2006","journal-title":"Digestive Diseases and Sciences"},{"issue":"18","key":"10.1002\/14651858.CD013157.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.11569\/wcjd.v16.i18.2002","article-title":"Therapeutic efficacy of omega-3 polyunsaturated fatty acid capsule in treatment of patients with non-alcoholic fatty liver disease","volume":"16","author":"Chen","year":"2008","journal-title":"World Chinese Journal of Digestology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"47","author":"Chen","year":"2015","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2015.05.009","article-title":"Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial","volume":"99","author":"Chen","year":"2015","journal-title":"Pharmacological Research"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ptr.6406","article-title":"Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled, double-blind clinical trial","volume":"33","author":"Cheraghpour","year":"2019","journal-title":"Phytotherapy Research"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/07315724.2020.1779850","article-title":"Hepatoprotective effect of Antrodia cinnamomea mycelium in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial","volume":"40","author":"Chiou","year":"2021","journal-title":"Journal of the American College of Nutrition"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0058|cit58","first-page":"1486","article-title":"Effect of pre\/probiotic mixture in children with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"176","author":"Chongsrisawat","year":"2017","journal-title":"European Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0059|cit59","first-page":"34","article-title":"The add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver disease","volume":"12","author":"Chou","year":"2006","journal-title":"Alternative Therapies in Health and Medicine"},{"issue":"16","key":"10.1002\/14651858.CD013157.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"e016334","DOI":"10.1161\/JAHA.119.016334","article-title":"Effects of epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers","volume":"9","author":"Climax","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.dsx.2018.03.006","article-title":"Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial","volume":"12","author":"Dabbaghmanesh","year":"2018","journal-title":"Diabetes and Metabolic Syndrome"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013157.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/S1590-8658(20)30861-6","article-title":"Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters and serological worsening markers in non-alcoholic fatty liver disease patients","volume":"52","author":"Dallio","year":"2020","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12986-018-0297-4","article-title":"Green cardamom increases sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial","volume":"15","author":"Daneshi-Maskooni","year":"2018","journal-title":"Nutrition and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000099","article-title":"Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis","volume":"49","author":"Dasarathy","year":"2015","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0065|cit65","first-page":"518a","article-title":"Randomized controlled trial of omega 3 fatty acids in the treatment of non-alcoholic steatohepatitis in type 2 diabetes mellitus","volume":"58","author":"Dasarathy","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S1590-8658(12)60738-5","article-title":"Beneficial effect of dietary supplementation with glucomannan in children with NAFLD: preliminary results","volume":"44","author":"Della Corte","year":"2012","journal-title":"Digestive and Liver Disease"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e0168216","DOI":"10.1371\/journal.pone.0168216","article-title":"Docosahexanoic acid plus vitamin D treatment improves features of NALFD in children with serum vitamin D deficiency: results from a single centre trial","volume":"11","author":"Della Corte","year":"2016","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02836467","article-title":"The state of insulin resistance in patients with nonalcoholic fatty liver and the intervention with gankangyin","volume":"11","author":"Deng","year":"2005","journal-title":"Chinese Journal of Integrative Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1478-3231.2009.02037.x","article-title":"Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis","volume":"29","author":"Balmer","year":"2009","journal-title":"Liver International"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","article-title":"Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis","volume":"4","author":"Dufour","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0072|cit72","first-page":"596a","article-title":"Probiotic VSL#3 improves liver histology in patients with nonalcoholic fatty liver disease - a proof of concept study","volume":"64","author":"Duseja","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3325\/cmj.2016.57.331","article-title":"Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial","volume":"57","author":"Ebrahimi-Mameghani","year":"2016","journal-title":"Croatian Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.clnu.2016.07.004","article-title":"Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: beneficial effects of supplementation with microalgae chlorella vulgaris: a double-blind placebo-controlled randomized clinical trial","volume":"36","author":"Ebrahimi-Mameghani","year":"2017","journal-title":"Clinical Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0075|cit75","first-page":"184","article-title":"Effects of L-carnitine supplementation on inflammatory factors and malondialdehyde in patients with nonalcoholic steatohepatitis (NASH)","volume":"9","author":"Eghtesadi","year":"2016","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/1735-1995.193178","article-title":"Do symbiotic and vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Ekhlasi","year":"2016","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0077|cit77","first-page":"278","article-title":"Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease","volume":"16","author":"Ekhlasi","year":"2017","journal-title":"Excli Journal"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0080|cit80","unstructured":"The effect of omega-3 fatty acids on non-alcoholic fatty liver disease www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-008275-34\/GB"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0081|cit81","unstructured":"A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease www.clinicaltrialsregister.eu\/ctr-search\/search?query=2009-017080-41"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study","volume":"114","author":"Faghihzadeh","year":"2015","journal-title":"British Journal of Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.arcmed.2014.11.001","article-title":"Oral coenzyme q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress","volume":"45","author":"Farhangi","year":"2014","journal-title":"Archives of Medical Research"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/07315724.2015.1021057","article-title":"Functions of coenzyme q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial","volume":"35","author":"Farsi","year":"2016","journal-title":"Journal of the American College of Nutrition"},{"issue":"3-4","key":"10.1002\/14651858.CD013157.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1024\/0300-9831\/a000528","article-title":"No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease","volume":"90","author":"Farzin","year":"2020","journal-title":"International Journal for Vitamin & Nutrition Research"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12011-019-02015-8","article-title":"The effect of zinc supplementation on steatosis severity and liver function enzymes in overweight\/obese patients with mild to moderate non-alcoholic fatty liver following calorie-restricted diet: a double-blind, randomized placebo-controlled trial","volume":"197","author":"Fathi","year":"2020","journal-title":"Biological Trace Element Research"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"126635","DOI":"10.1016\/j.jtemb.2020.126635","article-title":"The effects of zinc supplementation on metabolic profile and oxidative stress in overweight\/obese patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Fathi","year":"2020","journal-title":"Journal of Trace Elements in Medicine & Biology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14740\/gr1273","article-title":"Benefits of the therapy with abexol in patients with non-alcoholic fatty liver disease","volume":"13","author":"Fernandez-Travieso","year":"2020","journal-title":"Gastroenterology Research"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0091|cit91","first-page":"1280a","article-title":"Improvement in hepatic steatosis in nonalcoholic steatohepatitis in response to synbiotic supplementation","volume":"62","author":"Ferolla","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/nu8070397","article-title":"Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters but not on gut permeability in a population with nonalcoholic steatohepatitis","volume":"8","author":"Ferolla","year":"2016","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fendo.2020.00494","article-title":"Randomized clinical trial: Bergamot citrus and wild cardoon reduce liver steatosis and body weight in non-diabetic individuals aged over 50 years","volume":"11","author":"Ferro","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0094|cit94","first-page":"969","article-title":"Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver","volume":"5","author":"Foroughi","year":"2014","journal-title":"International Journal of Preventive Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013157.pub2-BIB0095|cit95","first-page":"10","article-title":"Effects of prebiotics on non-alcoholic fatty liver disease","volume":"26","author":"Gavrilescu","year":"2017","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/00365521.2018.1501091","article-title":"Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study","volume":"53","author":"Geier","year":"2018","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.aimed.2018.01.002","article-title":"Effects of turmeric and chicory seed supplementation on antioxidant and inflammatory biomarkers in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"5","author":"Ghaffari","year":"2018","journal-title":"Advances in Integrative Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17795\/compreped-6249","article-title":"Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease","volume":"4","author":"Ghergherehchi","year":"2013","journal-title":"Journal of Comprehensive Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12072-012-9387-y","article-title":"Impact of combined therapy with alpha-lipoic and ursodeoxycholic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety","volume":"7","author":"Gianturco","year":"2013","journal-title":"Hepatology International"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1365-2036.2009.04122.x","article-title":"Clinical trial: a nutritional supplement viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease","volume":"30","author":"Vilar Gomez","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0101|cit101","first-page":"35","article-title":"The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study","volume":"63","author":"Gonciarz","year":"2012","journal-title":"Journal of Physiology and Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0102|cit102","first-page":"439","article-title":"Effects of metformin combined with enteric bifid-triple viable capsule on nonalcoholic fatty liver disease","volume":"25","author":"Guo","year":"2016","journal-title":"Chinese Journal of New Drugs"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0104|cit104","first-page":"265","article-title":"A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease","volume":"9","author":"Hashemi","year":"2009","journal-title":"Hepatitis Monthly"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Heeboll","year":"2016","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jgr.2015.07.006","article-title":"Anti-inflammatory and antifatigue effect of Korean red ginseng in patients with nonalcoholic fatty liver disease","volume":"40","author":"Hong","year":"2016","journal-title":"Journal of Ginseng Research"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jgr.2020.07.004","article-title":"Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function","volume":"45","author":"Hong","year":"2021","journal-title":"Journal of Ginseng Research"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/09637486.2020.1746957","article-title":"Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial","volume":"71","author":"Hormoznejad","year":"2020","journal-title":"International Journal of Food Sciences & Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e96437","DOI":"10.5812\/hepatmon.96437","article-title":"Co-treatment with vitamin D supplementation and aerobic training in elderly women with vitamin D deficiency and NAFLD: a single-blind controlled trial","volume":"20","author":"Hoseini","year":"2020","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"102290","DOI":"10.1016\/j.ctim.2019.102290","article-title":"Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"49","author":"Hosseinabadi","year":"2020","journal-title":"Complementary Therapies in Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"100340","DOI":"10.1016\/j.hermed.2020.100340","article-title":"Effects of green coffee extract supplementation on glycemic indexes, leptin, and obesity values in patients with non-alcoholic fatty liver disease","volume":"22","author":"Hosseinabadi","year":"2020","journal-title":"Journal of Herbal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0112|cit112","first-page":"e60746","article-title":"The effect of a single intramuscular injection of cholecalciferol on the serum levels of vitamin D, adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver disease (NAFLD): a randomized, controlled clinical trial","volume":"20","author":"Hosseini","year":"2018","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"931","DOI":"10.12669\/pjms.334.12571","article-title":"Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients","volume":"33","author":"Hussain","year":"2017","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3904\/kjim.2013.28.4.439","article-title":"Effects of d-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease","volume":"28","author":"Illnait","year":"2013","journal-title":"Korean Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ptr.6826","article-title":"Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled clinical trial","volume":"35","author":"Izadi","year":"2021","journal-title":"Phytotherapy Research"},{"issue":"109","key":"10.1002\/14651858.CD013157.pub2-BIB0116|cit116","first-page":"23","article-title":"Treatment effects of probiotic in non alcoholic fatty liver disease","volume":"25","author":"Jameshorani","year":"2017","journal-title":"Journal of Zanjan University of Medical Sciences and Health Services"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","article-title":"Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"166","author":"Janczyk","year":"2015","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e46017","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial","volume":"19","author":"Javadi","year":"2017","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0119|cit119","unstructured":"Javanmardi MA Mohammad Shahi M Seyedian SS Haghighizadeh MH Effects of phytosterol supplementation on serum levels of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial Journal of the American College of Nutrition 10.1080\/07315724.2018.1466739"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"e016914","DOI":"10.1136\/bmjopen-2017-016914","article-title":"Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol","volume":"7","author":"Jazayeri-Tehrani","year":"2017","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12986-019-0331-1","article-title":"Nano-curcumin improves glucose indices, lipids, inflammation, and nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial","volume":"16","author":"Jazayeri-Tehrani","year":"2019","journal-title":"Nutrition & Metabolism"},{"issue":"32","key":"10.1002\/14651858.CD013157.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.3748\/wjg.v23.i32.5977","article-title":"New botanical drug, hl tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: a placebo-controlled, randomized, phase II trial","volume":"23","author":"Jeong","year":"2017","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"683028","DOI":"10.3389\/fimmu.2021.683028","article-title":"Nutrigenetic interactions might modulate the antioxidant and anti-inflammatory status in mastiha-supplemented patients with NAFLD","volume":"12","author":"Kanoni","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0124|cit124","unstructured":"Mastiha treatment for obese with NAFLD diagnosis clinicaltrials.gov\/ct2\/show\/NCT03135873"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"101259","DOI":"10.1016\/j.ctcp.2020.101259","article-title":"The effects of sumac (Rhus coriaria l) powder supplementation in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"41","author":"Kazemi","year":"2020","journal-title":"Complementary Therapies in Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0126|cit126","first-page":"12","article-title":"N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease","volume":"10","author":"Khoshbaten","year":"2010","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0127|cit127","first-page":"S329","article-title":"Prebiotics' plus probiotics' effect on the patients with nonalcoholic fatty liver disease","volume":"14","author":"Khutsishvili","year":"2020","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0128|cit128","first-page":"13","article-title":"Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study","volume":"13","author":"Kobyliak","year":"2018","journal-title":"Minerva Medica"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/S0168-8278(17)31218-7","article-title":"Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial","volume":"66","author":"Kobyliak","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0131|cit131","first-page":"14","article-title":"Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Kooshki","year":"2020","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0133|cit133","first-page":"711a","article-title":"Changes in adipose tissue insulin resistance correlate with changes in alt and lobular inflammation in children enrolled in the tonic trial","volume":"54","author":"Bell","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"16","key":"10.1002\/14651858.CD013157.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the tonic randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"9575878","DOI":"10.1155\/2020\/9575878","article-title":"Corrigendum to \"The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease\"","volume":"2020","author":"Lewis","year":"2020","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1751583","DOI":"10.1155\/2018\/1751583","article-title":"The effect of a hydrolyzed polysaccharide dietary supplement on biomarkers in adults with nonalcoholic fatty liver disease","volume":"2018","author":"Lewis","year":"2018","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11655-010-0023-1","article-title":"Treatment of non-alcoholic fatty liver disease by qianggan capsule ((sic))","volume":"16","author":"Li","year":"2010","journal-title":"Chinese Journal of Integrative Medicine"},{"issue":"22","key":"10.1002\/14651858.CD013157.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"22","author":"Li","year":"2016","journal-title":"World Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","article-title":"Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"52","author":"Loguercio","year":"2012","journal-title":"Free Radical Biology and Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1475-2891-12-166","article-title":"Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial","volume":"12","author":"Magosso","year":"2013","journal-title":"Nutrition Journal"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/ajg.2009.719","article-title":"L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial","volume":"105","author":"Malaguarnera","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0143|cit143","first-page":"241","article-title":"Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: a pilot randomized placebo-controlled, clinical trial","volume":"19","author":"Mansour","year":"2020","journal-title":"Excli Journal"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"Journal of Digestive Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0145|cit145","first-page":"1","article-title":"Siliphos selenium methionine alpha lipoic acid for non-alcoholic fatty liver disease: results of a pilot study","volume":"5","author":"Mart\u00ednez-Rodr\u00edguez Leonardo","year":"2014","journal-title":"Journal of Clinical & Experimental Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0146|cit146","first-page":"722","article-title":"Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis - a double-blind, randomized, parallel-group, placebo-controlled prospective clinical study","volume":"50","author":"Miglio","year":"2000","journal-title":"Arzneimittel-Forschung-Drug Research"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"Mofidi","year":"2017","journal-title":"British Journal of Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jbmt.2020.02.021","article-title":"Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease","volume":"24","author":"Moradi","year":"2020","journal-title":"Journal of Bodywork and Movement Therapies"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"126659","DOI":"10.1016\/j.jtemb.2020.126659","article-title":"A pilot study of the effects of chromium picolinate supplementation on serum fetuin-a, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: a double-blind, placebo-controlled trial","volume":"63","author":"Moradi","year":"2021","journal-title":"Journal of Trace Elements in Medicine and Biology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7762\/cnr.2021.10.1.36","article-title":"Probiotic yogurt fortified with vitamin D can improve glycemic status in non-alcoholic fatty liver disease patients: a randomized clinical trial","volume":"10","author":"Morvaridzadeh","year":"2021","journal-title":"Clinical Nutrition Research"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"Journal of Dairy Science"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jff.2015.08.031","article-title":"Probiotic yogurt improves body mass index and fasting insulin levels without affecting serum leptin and adiponectin levels in non-alcoholic fatty liver disease (NAFLD)","volume":"18","author":"Nabavi","year":"2015","journal-title":"Journal of Functional Foods"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0153|cit153","first-page":"12","article-title":"The effects of probiotic yogurt on metabolic factors in nonalcoholic fatty liver disease","volume":"20","author":"Nabavi","year":"2016","journal-title":"Scientific Journal of Kurdistan University of Medical Sciences"},{"issue":"99","key":"10.1002\/14651858.CD013157.pub2-BIB0154|cit154","first-page":"25","article-title":"Effect of probiotic yogurt on enzymes and ecogenicity of liver in individuals with non alcoholic fatty liver disease: a double-blind randomized controlled clinical trial","volume":"23","author":"Rafraf","year":"2015","journal-title":"Journal of Zanjan University of Medical Sciences and Health Services"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0155|cit155","first-page":"55","article-title":"The effect of probiotic and conventional yogurt consumption on anthropometric parameters in individuals with non-alcoholic fatty liver disease","volume":"16","author":"Rafraf","year":"2014","journal-title":"Journal of Babol University of Medical Sciences"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0261-5614(16)30393-4","article-title":"Effect of the medical walking and leucine enriched amino acid containing food for female nonalcoholic fatty liver disease: randomized controlled trial","volume":"35","author":"Naganuma","year":"2016","journal-title":"Clinical Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/07315724.2016.1267597","article-title":"Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases","volume":"36","author":"Navekar","year":"2017","journal-title":"Journal of the American College of Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0158|cit158","unstructured":"Safety and efficacy of Hoodia gordonii for treatment of non-alcoholic fatty liver disease (NAFLD) clinicaltrials.gov\/ct2\/show\/NCT00816465"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0159|cit159","unstructured":"Fish oil and diet for the treatment of non-alcoholic steatohepatitis (NASH) clinicaltrials.gov\/ct2\/show\/NCT00845845"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0160|cit160","unstructured":"Placebo controlled study using lovaza as treatment for non-alcoholic fatty liver disease clinicaltrials.gov\/ct2\/show\/NCT00941642"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0161|cit161","unstructured":"The effect of protandim on non-alcoholic steatohepatitis clinicaltrials.gov\/ct2\/show\/NCT00977730"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0162|cit162","unstructured":"Role of vitagliptin and vitamin D in the treatment of non-alcoholic fatty liver disease (NAFLD) clinicaltrials.gov\/ct2\/show\/NCT01083992"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0163|cit163","unstructured":"Effect on liver histology of vitamin D in patients with non-alcoholic steatohepatitis clinicaltrials.gov\/ct2\/show\/NCT01623024"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0164|cit164","unstructured":"Effect of vitamin E on non-alcoholic fatty liver disease clinicaltrials.gov\/ct2\/show\/NCT02690792"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0165|cit165","unstructured":"Efficacy of phosphatidylcholine in NAFLD clinicaltrials.gov\/show\/NCT04411862"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"A847","DOI":"10.1016\/S0016-5085(09)63906-8","article-title":"A randomized, masked, controlled study of omega-3 polyunsaturated fatty acid vs monounsaturated fatty acid diet supplementation for the treatment of nonalcoholic fatty liver disease","volume":"136","author":"Nelson","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0167|cit167","first-page":"12","article-title":"Antioxidant activity of hydroxytyrosol and vitamin E reduces systemic inflammation in children with paediatric NAFLD","volume":"12","author":"Mosca","year":"2020","journal-title":"Digestive & Liver Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.dld.2019.12.138","article-title":"The anti-inflammatory effects of hydroxytyrosol and vitamin E on paediatric NAFLD","volume":"52","author":"Mosca","year":"2020","journal-title":"Digestive and Liver Disease"},{"issue":"11-12","key":"10.1002\/14651858.CD013157.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1365-2036.2006.03161.x","article-title":"Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease","volume":"24","author":"Nobili","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hep.22336","article-title":"Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial","volume":"48","author":"Nobili","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"A781","DOI":"10.1016\/S0016-5085(08)63648-3","article-title":"Lifestyle intervention and antioxidants in children with nonalcoholic fatty liver disease: a randomized, controlled trial","volume":"134","author":"Nobili","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","article-title":"Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children","volume":"23","author":"Nobili","year":"2013","journal-title":"Nutrition Metabolism and Cardiovascular Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.2010.192401","article-title":"Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial","volume":"96","author":"Nobili","year":"2011","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clinical Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.obmed.2020.100278","article-title":"Effect of omega-3 fatty acid supplementation on inflammatory markers and insulin resistance indices in patient with type 2 diabetes and nonalcoholic fatty liver: a randomized double-blind clinical trial","volume":"19","author":"Orang","year":"2020","journal-title":"Obesity Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0176|cit176","first-page":"1268a","article-title":"Prebiotic supplementation with inulin following metronidazole therapy achieves greater alt reduction in non-alcoholic fatty liver disease (NAFLD): a randomised double-blind placebo controlled trial","volume":"62","author":"Orr","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0177|cit177","first-page":"10","article-title":"Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study","volume":"10","author":"Oscarsson","year":"2018","journal-title":"Journal of Clinical Lipidology"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","article-title":"A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease","volume":"25","author":"Pacifico","year":"2015","journal-title":"Nutrition Metabolism and Cardiovascular Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013157.pub2-BIB0179|cit179","first-page":"28","article-title":"Vitamin E and non-alcoholic fatty liver disease","volume":"26","author":"Palamaru","year":"2017","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"issue":"119","key":"10.1002\/14651858.CD013157.pub2-BIB0180|cit180","first-page":"2099","article-title":"Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"59","author":"Panahi","year":"2012","journal-title":"Hepato-Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FJC.0000000000000406","article-title":"Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"68","author":"Panahi","year":"2016","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-0043-100019","article-title":"Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial","volume":"67","author":"Panahi","year":"2017","journal-title":"Drug Research"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"100165","DOI":"10.1016\/j.obmed.2019.100165","article-title":"The effects of Crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized placebo-controlled study","volume":"17","author":"Parsi","year":"2020","journal-title":"Obesity Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7762\/cnr.2020.9.1.11","article-title":"Effects of quercetin supplementation on hematological parameters in non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"9","author":"Pasdar","year":"2020","journal-title":"Clinical Nutrition Research"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5152\/tjg.2018.17297","article-title":"Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease","volume":"29","author":"Pervez","year":"2018","journal-title":"Turkish Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"102494","DOI":"10.1016\/j.ctim.2020.102494","article-title":"Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial","volume":"52","author":"Pervez","year":"2020","journal-title":"Complementary Therapies in Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/2008-7802.173051","article-title":"The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease","volume":"7","author":"Pezeshki","year":"2016","journal-title":"International Journal of Preventive Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0188|cit188","first-page":"S99","article-title":"Effect of synbiotic supplementation in children with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"103","author":"Poparn","year":"2020","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0189|cit189","unstructured":"Poulos JE Kalogerinis PT Milanov V Kalogerinis CT Poulos EJ The effects of vitamin E, silymarin and carnitine on the metabolic abnormalities associated with nonalcoholic liver disease Journal of Dietary Supplements 10.1080\/19390211.2021.1874587"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/ptr.6791","article-title":"The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"34","author":"Pour","year":"2020","journal-title":"Phytotherapy Research"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"e0133496","DOI":"10.1371\/journal.pone.0133496","article-title":"Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin e2 in nonalcoholic fatty liver disease associated with hyperlipidemia: a randomized clinical trial","volume":"10","author":"Qin","year":"2015","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEG.S234698","article-title":"Effect of ginger powder supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"13","author":"Rafie","year":"2020","journal-title":"Clinical and Experimental Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"e34897","DOI":"10.5812\/hepatmon.34897","article-title":"Ginger supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"16","author":"Rahimlou","year":"2016","journal-title":"Hepatitis Monthly"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ptr.5659","article-title":"Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial","volume":"30","author":"Rahmani","year":"2016","journal-title":"Phytotherapy Research"},{"issue":"29","key":"10.1002\/14651858.CD013157.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.11569\/wcjd.v18.i29.3151","article-title":"Efficacy of silibin capsules in the treatment of metabolism syndrome-related fatty liver disease: an analysis of 30 cases","volume":"18","author":"Ruan","year":"2010","journal-title":"World Chinese Journal of Digestology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0196|cit196","first-page":"82","article-title":"The effect of gerilact on non-alcoholic fatty liver disease","volume":"27","author":"Sadrkabir","year":"2020","journal-title":"Journal of Kerman University of Medical Sciences"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0197|cit197","first-page":"A106","article-title":"Vitamin D supplementation in patients with nonalcoholic fatty liver disease - a randomized controlled trial","volume":"34","author":"Sakpal","year":"2015","journal-title":"Indian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"62?7","DOI":"10.1002\/jgh3.12010","article-title":"Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"1","author":"Sakpal","year":"2017","journal-title":"JGH Open"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1017\/S0007114520001403","article-title":"Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial","volume":"124","author":"Sangouni","year":"2020","journal-title":"British Journal of Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"102428","DOI":"10.1016\/j.ctim.2020.102428","article-title":"Effects of garlic powder supplementation on insulin resistance, oxidative stress, and body composition in patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial","volume":"51","author":"Sangouni","year":"2020","journal-title":"Complementary Therapies in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.25805","article-title":"Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study","volume":"56","author":"Bell","year":"2012","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: Pivens trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemporary Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"18","key":"10.1002\/14651858.CD013157.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0206|cit206","first-page":"63","article-title":"Double-blind randomized placebo controlled clinical trial of herbal compound livomap (ma-579) in patients with non alcoholic fatty liver disease (NAFLD)","volume":"4","author":"Saxena","year":"2013","journal-title":"Journal of Ayurveda and Integrative Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clinical and Molecular Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0208|cit208","first-page":"1106a","article-title":"Dietary counselling focusing only on fructose consumption improves hepatic inflammation in patients with NAFLD-A prospective, controlled, randomized open-label study (Nuces NASH)","volume":"66","author":"Schattenberg","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0209|cit209","first-page":"53","article-title":"High-dose n-3 fatty acid treatment in non-alcoholic fatty liver disease is independently associated with reduced hepatic steatosis and improved hepatic insulin sensitivity","volume":"31","author":"Bhatia","year":"2014","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0210|cit210","first-page":"1","article-title":"Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the Welcome study","volume":"31","author":"Scorletti","year":"2014","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0212|cit212","first-page":"55","article-title":"Investigation of the effects of synbiotic treatment on gut microbiota composition in patients with non-alcoholic fatty liver disease and type 2 diabetes","volume":"37","author":"Scorletti","year":"2020","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cct.2018.05.010","article-title":"Design and rationale of the Insyte study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease","volume":"71","author":"Scorletti","year":"2018","journal-title":"Contemporary Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"Journal of the American College of Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e12299","DOI":"10.5812\/hepatmon.45609","article-title":"Effects of green coffee bean extract supplementation on patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"17","author":"Shahmohammadi","year":"2017","journal-title":"Hepatitis Monthly"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0218|cit218","first-page":"531","article-title":"Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial","volume":"4","author":"Shavakhi","year":"2013","journal-title":"International Journal of Preventive Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2277-9175.174962","article-title":"Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial","volume":"5","author":"Soleimani","year":"2016","journal-title":"Advanced Biomedical Research"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2147\/DMSO.S254555","article-title":"Therapeutic effects of garlic on hepatic steatosis in nonalcoholic fatty liver disease patients: a randomized clinical trial","volume":"13","author":"Soleimani","year":"2020","journal-title":"Diabetes, Metabolic Syndrome and Obesity Targets and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ptr.6937","article-title":"Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: a randomized clinical trial","volume":"35","author":"Soleimani","year":"2021","journal-title":"Phytotherapy Research"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0222|cit222","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Caspian Journal of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"575","DOI":"10.6026\/97320630010575","article-title":"Data from a randomized and controlled trial of l-carnitine prescription for the treatment for non- alcoholic fatty liver disease","volume":"10","author":"Somi","year":"2014","journal-title":"Bioinformation"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1017\/S0007114520000495","article-title":"Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial","volume":"123","author":"Song","year":"2020","journal-title":"British Journal of Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.dld.2007.10.003","article-title":"Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease","volume":"40","author":"Spadaro","year":"2008","journal-title":"Digestive and Liver Disease"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"e14993","DOI":"10.5812\/hepatmon.14993","article-title":"Green tea in non-alcoholic fatty liver disease: a double blind randomized clinical trial","volume":"17","author":"Tabatabaee","year":"2017","journal-title":"Hepatitis Monthly"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0227|cit227","first-page":"415","article-title":"Effects of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD)","volume":"34","author":"Taghvaei","year":"2018","journal-title":"Acta Medica Mediterranea"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0228|cit228","first-page":"162","article-title":"A randomized, unblinded pilot trial of essential phospholipids in Chinese subjects with nonalcoholic fatty liver disease (NASH)","volume":"26","author":"Tan","year":"2011","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/nu10081126","article-title":"Evaluation of a high concentrate omega-3 for correcting the omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (condin)","volume":"10","author":"Tobin","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.34172\/hpp.2020.56","article-title":"Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: a clinical trial","volume":"10","author":"Tutunchi","year":"2020","journal-title":"Health Promotion Perspectives"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"104770","DOI":"10.1016\/j.phrs.2020.104770","article-title":"Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: effects on metabolic parameters, anthropometric indices, and expression of ppar-alpha, ucp1, and ucp2 genes","volume":"156","author":"Tutunchi","year":"2020","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jcp.29870","article-title":"Expression of NF-kappaB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-combined effects of oleoylethanolamide supplementation and calorie restriction: a triple-blind randomized controlled clinical trial","volume":"236","author":"Tutunchi","year":"2021","journal-title":"Journal of Cellular Physiology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0233|cit233","first-page":"196","article-title":"L-carnitine therapy in non-alcoholic steatohepatitis","volume":"11","author":"Uygun","year":"2000","journal-title":"Turkish Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3748\/wjg.14.1598","article-title":"Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children","volume":"14","author":"Wang","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0236|cit236","first-page":"S939","article-title":"Effect of herb formula xiao-zhi-hua-xian-tang against nonalcoholic steatohepatitis with advanced fibrosis: a preliminary clinical study","volume":"11","author":"Wang","year":"2017","journal-title":"Hepatology International"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0237|cit237","first-page":"101","article-title":"[Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease]","volume":"57","author":"Wang","year":"2018","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0238|cit238","first-page":"A163","article-title":"Clinical observation on the treatment of nonalcoholic fatty liver with probiotics","volume":"5","author":"Wang","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Annals of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-1746.2012.07286.x","article-title":"Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial","volume":"28","author":"Wong","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0241|cit241","first-page":"A513","article-title":"Berberine vs. pioglitazone for treatment of nonalcoholic fatty liver disease and its associated impaired glucose metabolism","volume":"63","author":"Yan","year":"2014","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0242|cit242","first-page":"S36","article-title":"Pioglitazone versus berberine for treatment of non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus","volume":"55","author":"Yan","year":"2012","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0243|cit243","first-page":"S351","article-title":"Berberine increases serum osteocalcin levels and improves early phase of insulin secretion in non-alcoholic fatty liver disease patients with impaired glucose metabolism","volume":"57","author":"Yan","year":"2014","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"e0134172","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLOS One"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/09637486.2016.1161011","article-title":"Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study","volume":"67","author":"Yari","year":"2016","journal-title":"International Journal of Food Sciences and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41430-020-0679-3","article-title":"The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial","volume":"75","author":"Yari","year":"2021","journal-title":"European Journal of Clinical Nutrition"},{"issue":"Supp 1","key":"10.1002\/14651858.CD013157.pub2-BIB0247|cit247","first-page":"82","article-title":"The effect of oral \u03b2-glucan supplement on liver echogenicity and enzymes in non-alcoholic fatty liver disease treating with hypocaloric diet and vitamin E","volume":"20","author":"Youshari","year":"2017","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ctim.2018.09.010","article-title":"The effects of Zataria multiflora boiss (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: a randomized double-blind placebo-controlled clinical trial","volume":"41","author":"Zamani","year":"2018","journal-title":"Complementary Therapies in Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S0168-8278(20)31377-5","article-title":"The efficacy of vitamin D supplementation on NAFLD: a randomized, double-blind, placebo-controlled 12- month trial on 311 patients","volume":"73","author":"Mikolasevic","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/dom.14129","article-title":"Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Zanko","year":"2020","journal-title":"Diabetes Obesity & Metabolism"},{"issue":"20","key":"10.1002\/14651858.CD013157.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/MD.0000000000000758","article-title":"A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthrocyanin in patients with nonalcoholic fatty liver disease","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"issue":"41","key":"10.1002\/14651858.CD013157.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.3748\/wjg.14.6395","article-title":"Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia","volume":"14","author":"Zhu","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1139\/apnm-2016-0689","article-title":"Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial","volume":"42","author":"Zohrer","year":"2017","journal-title":"Applied Physiology, Nutrition, and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/nu9080870","article-title":"Effect of Mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study","volume":"9","author":"Abenavoli","year":"2017","journal-title":"Nutrients"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S1590-8658(16)30151-7","article-title":"Efficacy of Mediterranean diet and antioxidants in overweight patients with non-alcoholic fatty liver disease","volume":"48","author":"Abenavoli","year":"2016","journal-title":"Digestive and Liver Disease"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","article-title":"Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver","volume":"81","author":"Akcam","year":"2011","journal-title":"International Journal for Vitamin and Nutrition Research"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0257|cit257","first-page":"624a","article-title":"Berberine with alfa lipoic acid (ALA) in non alcoholic steato-hepatitis (NASH). A randomized double blinded placebo control trial. A clinical pilot - the Banish Trial","volume":"60","author":"Basu","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0258|cit258","first-page":"43","article-title":"Berberine with alfa lipoic acid (ALA) in non alcoholic steatohepatitis (NASH). A randomized double blinded placebo control trial. A clinical pilot - the Banish Trial","volume":"17","author":"Basu","year":"2015","journal-title":"Journal of the International Hepato Pancreato Biliary Association"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013157.pub2-BIB0259|cit259","first-page":"S10","article-title":"Berberine with alfa lipoic acid (ALA) in non alcoholic steatohepatitis (NASH). A randomized double blinded placebo control trial. A clinical pilot: the Banish Trial","volume":"8","author":"Basu","year":"2014","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0260|cit260","first-page":"11","article-title":"The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease","volume":"11","author":"Chambers","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1039\/c3fo60495k","article-title":"Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans","volume":"5","author":"Chang","year":"2014","journal-title":"Food and Function"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0262|cit262","first-page":"223","article-title":"The efficacy of ursodeoxycholic acid, probiotics vs. diet and exercise in the treatment of NAFLD: an open-labelled prospective randomized trial","volume":"27","author":"Dela Cruz","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0263|cit263","first-page":"124","article-title":"Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment","volume":"16","author":"Ersoz","year":"2005","journal-title":"Turkish Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0264|cit264","first-page":"16","article-title":"The effect of silymarin on non-alcoholic fatty liver disease of children","volume":"6","author":"Famouri","year":"2017","journal-title":"Journal of Herbmed Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.nut.2013.07.023","article-title":"Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease","volume":"30","author":"Guo","year":"2014","journal-title":"Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"e6099","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi","year":"2012","journal-title":"Hepatitis Monthly"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-013-0136-3","article-title":"Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose","volume":"34","author":"Han","year":"2014","journal-title":"Clinical Drug Investigation"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/1319-3767.65197","article-title":"Grape seed extract to improve liver function in patients with nonalcoholic fatty liver change","volume":"16","author":"Khoshbaten","year":"2010","journal-title":"Saudi Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0269|cit269","unstructured":"Mahmoudi L Asadi S Al-Mousavi Z Niknam R A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease Clinical Nutrition"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0270|cit270","unstructured":"Efficacy and safety of diamel in patients with nonalcoholic steatohepatitis clinicaltrials.gov\/ct2\/show\/NCT00820651"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0271|cit271","unstructured":"Omega 3 supplementation in children with non alcoholic fatty liver clinicaltrials.gov\/show\/NCT04281121"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0272|cit272","first-page":"4549614","article-title":"Reduction of liver span and parameters of inflammation in nonalcoholic fatty liver disease patients treated with lycosome formulation of phosphatidylcholine: a preliminary report","volume":"2018","author":"Petyaev","year":"2018","journal-title":"International Journal of Chronic Diseases Print"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"101710","DOI":"10.1016\/j.redox.2020.101710","article-title":"Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis","volume":"37","author":"Podszun","year":"2020","journal-title":"Redox Biology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0274|cit274","first-page":"112","article-title":"Effects of low dose betaine in subjects with mild fatty liver","volume":"58","author":"Saarinen","year":"2011","journal-title":"Annals of Nutrition and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17116\/terarkh201688258-63","article-title":"[Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis]","volume":"88","author":"Semiserin","year":"2016","journal-title":"Terapevticheskii Arkhiv"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4103\/0257-7941.160866","article-title":"Efficacy of herbomineral compounds and pathya (ayurvedic dietary regime and physical exercise) in the management of yakrt roga (non-alcoholic fatty liver disease)","volume":"34","author":"Singhal","year":"2015","journal-title":"Ancient Science of Life"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ctim.2007.08.004","article-title":"The effect of quyuhuatantongluo decoction on the non-alcoholic steatohepatitis","volume":"16","author":"Zhang","year":"2008","journal-title":"Complementary Therapies in Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0278|cit278","unstructured":"To explore the protective effect of Lycium barbarum polysaccharide combined with exercise intervention on nonalcoholic fatty liver disease based on gut microbiota: a randomized controlled trial www.chictr.org.cn\/hvshowproject.aspx?id=43624"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0279|cit279","unstructured":"Efficacy and safety of caffeic acid in nonalcoholic fatty liver disease www.chictr.org.cn\/hvshowproject.aspx?id=49625"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0280|cit280","unstructured":"Effect of herbal blend in non-alcoholic subjects with elevated fatty liver index ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=41930&EncHid=&userName=CTRI\/2020\/05\/025322"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0281|cit281","unstructured":"To evaluate the efficacy of sarvakalpa-ghan-vati in management of non-alcoholic liver disorder ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=44069&EncHid=&userName=2020\/07\/026362"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13063-020-4068-y","article-title":"Effect of daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial","volume":"21","author":"Han","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0283|cit283","unstructured":"Effects of naringenin supplement on non-alcoholic fatty liver disease www.irct.ir\/trial\/49713"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0284|cit284","unstructured":"Investigation the effect of the sumac powder consumption on patients with non-alcoholic fatty liver www.irct.ir\/trial\/43090"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0285|cit285","unstructured":"Evaluating the effect of spirulina in non-alcoholic fatty liver patient www.irct.ir\/trial\/46330"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0286|cit286","unstructured":"Zinc supplementation in treatment of obese children and adolescents with nonalcoholic fatty liver disease www.irct.ir\/trial\/48543"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12876-015-0400-5","article-title":"Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol","volume":"15","author":"Lambert","year":"2015","journal-title":"BMC Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0288|cit288","unstructured":"The effects of ginger on nonalcoholic fatty liver disease clinicaltrials.gov\/ct2\/show\/NCT02289235"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0289|cit289","unstructured":"Prebiotics in patients with non-alcoholic liver disease clinicaltrials.gov\/ct2\/show\/NCT02642172"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0290|cit290","unstructured":"Polyunsaturated fatty acids in patients with NAFLD clinicaltrials.gov\/ct2\/show\/NCT02647294"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0291|cit291","unstructured":"Probiotics in the treatment of NAFLD clinicaltrials.gov\/ct2\/show\/NCT02764047"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0292|cit292","unstructured":"Effects of carnitine supplementation on liver and muscle clinicaltrials.gov\/ct2\/show\/NCT03439917"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0293|cit293","unstructured":"Probiotics in NASH Patients - PROBILIVER TRIAL (NASH) clinicaltrials.gov\/ct2\/show\/NCT03467282"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0294|cit294","unstructured":"Effect of probiotics in non-alcoholic fatty liver disease and steatohepatitis clinicaltrials.gov\/ct2\/show\/NCT04175392"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0295|cit295","unstructured":"An investigator initiated prospective, four arms randomized comparative study of efficacy and safety of saroglitazar, vitamin E and life style modification in patients with nonalcoholic fatty liver disease (NAFLD)\/ non-alcoholic steatohepatitis (NASH) clinicaltrials.gov\/ct2\/show\/NCT04193982"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0296|cit296","unstructured":"Vitamin E and DHA-EE on NAFLD - randomized, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD) clinicaltrials.gov\/ct2\/show\/NCT04198805"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0297|cit297","unstructured":"Metabolic cofactor supplementation in obese patients with non-alcoholic fatty liver disease clinicaltrials.gov\/show\/NCT04330326"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0298|cit298","unstructured":"Effect of alpha lipoic acid on non-alcoholic fatty liver diseases clinicaltrials.gov\/show\/NCT04475276"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0299|cit299","unstructured":"None of the outcomes of interest for this review will be reported in this trial Effects of probiotics (P pentosaceus, l lactis or l helveticus) in NASH clinicaltrials.gov\/show\/NCT04555434"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0300|cit300","unstructured":"Role of probiotics in treatment of pediatric NAFLD patients by assessing with fibroscan clinicaltrials.gov\/show\/NCT04671186"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0301|cit301","unstructured":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Tocovid Suprabio 200mg in non-alcoholic fatty liver (NAFL) clinicaltrials.gov\/ct2\/show\/NCT04704063"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0302|cit302","unstructured":"S.P.Pro liver powder is used to improve liver and metabolic indexes in people with non-alcoholic fatty liver disease clinicaltrials.gov\/ct2\/show\/NCT04718051"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1139\/bcb-2014-0136","article-title":"Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol","volume":"93","author":"Wicklow","year":"2015","journal-title":"Biochemistry and Cell Biology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12325-018-0670-8","article-title":"Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China: a multicenter, randomized, placebo-controlled trial design","volume":"35","author":"Zang","year":"2018","journal-title":"Advances in Therapy"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.mcna.2007.06.001","article-title":"Nonalcoholic fatty liver disease as a complication of insulin resistance","volume":"91","author":"Abdelmalek","year":"2007","journal-title":"Medical Clinics of North America"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1586\/17474124.2013.842893","article-title":"Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?","volume":"7","author":"Abenavoli","year":"2013","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/17474124.2015.1004312","article-title":"Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease","volume":"9","author":"Abenavoli","year":"2015","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"17-18","key":"10.1002\/14651858.CD013157.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discovery Today"},{"issue":"16","key":"10.1002\/14651858.CD013157.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12906-016-1540-z","article-title":"Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers","volume":"17","author":"Al-Muzafar","year":"2017","journal-title":"BMC Complementary and Alternative Medicine"},{"issue":"16","key":"10.1002\/14651858.CD013157.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2012.04.041","article-title":"S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility","volume":"57","author":"Anstee","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study","volume":"61","author":"Gitlin","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.21827","article-title":"Incidence and natural course of fatty liver in the general population: the Dionysos Study","volume":"46","author":"Bedogni","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"e0143293","DOI":"10.1371\/journal.pone.0143293","article-title":"Sleep disruption and daytime sleepiness correlating with disease severity and insulin resistance in non-alcoholic fatty liver disease: a comparison with healthy controls","volume":"10","author":"Bernsmeier","year":"2015","journal-title":"PLOS One"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0320|cit320","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013103","article-title":"Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis","author":"Best","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0322|cit322","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013156.pub2","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis","author":"Buzzetti","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/MEG.0b013e32835f0786","article-title":"Alcoholic liver disease\/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease","volume":"25","author":"Cerovic","year":"2013","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013157.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0329|cit329","doi-asserted-by":"crossref","unstructured":"Clearfield E Miller V Nadglowski J Barradas K Al Naber J Sanyal AJ coreNASH: multi-stakeholder consensus on core outcomes for decision making about nonalcoholic steatohepatitis treatment Hepatology Communications 2021 5 5 774 85","DOI":"10.1002\/hep4.1678"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","article-title":"Electronic health records to facilitate clinical research","volume":"106","author":"Cowie","year":"2017","journal-title":"Clinical Research in Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/00365520510012217","article-title":"Histological characteristics and prognosis in patients with fatty liver","volume":"40","author":"Dam-Larsen","year":"2005","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD013157.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1440-1746.2009.05831.x","article-title":"Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population","volume":"24","author":"Dassanayake","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/sim.5512","article-title":"Network meta-analysis models to account for variability in treatment definitions: application to dose effects","volume":"32","author":"Del Giovane","year":"2013","journal-title":"Statistics in Medicine"},{"issue":"7-8","key":"10.1002\/14651858.CD013157.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0335|cit335","unstructured":"Dias S Sutton AJ Welton NJ Ades AE NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012) nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD3-Heterogeneity.final-report.08.05.12.pdf"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0336|cit336","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012) silo.tips\/download\/nice-dsu-technical-support-document-1-introduction-to-evidence-synthesis-for-dec"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0337|cit337","unstructured":"Dias S Welton NJ Sutton AJ Caldwell DM Lu G Ades AE NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014) nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD4-Inconsistency.final_.15April2014.pdf"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0338|cit338","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated September 2016) www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0088912\/pdf\/PubMedHealth_PMH0088912.pdf"},{"issue":"13","key":"10.1002\/14651858.CD013157.pub2-BIB0339|cit339","first-page":"285","article-title":"On observations relating to several quantities","volume":"6","author":"Edgeworth","year":"1887","journal-title":"Hermathena"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/j.gastro.2019.05.064","article-title":"Toward more accurate nomenclature for fatty liver diseases","volume":"157","author":"Eslam","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0342|cit342","unstructured":"EQ-5D Instruments | About EQ-5D, 2018 euroqol.org\/eq-5d-instruments\/"},{"issue":"17","key":"10.1002\/14651858.CD013157.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3748\/wjg.v20.i17.4987","article-title":"NAFLD prevalence differs among Hispanic subgroups: the multi-ethnic study of atherosclerosis","volume":"20","author":"Fleischman","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0344|cit344","doi-asserted-by":"crossref","unstructured":"Gurusamy K Walmsley M Davidson BR Frier C Fuller B Madden A Top research priorities in liver and gallbladder disorders in the United Kingdom BMJ Open 2019 9 3 e025045","DOI":"10.1136\/bmjopen-2018-025045"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemporary Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"7414","key":"10.1002\/14651858.CD013157.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research edition)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0349|cit349","unstructured":"Higgins JT Altman DG Chapter 8. Assessing risk of bias in included studies. In: Higgins JT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0350|cit350","unstructured":"Higgins JT Deeks JJ Chapter 16. Special topics in statistics. In: Higgins JT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org."},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cgh.2016.07.031","article-title":"Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial","volume":"15","author":"Houghton","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0354|cit354","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"21","key":"10.1002\/14651858.CD013157.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrcardio.2015.33","article-title":"Registry-based randomized clinical trials - a new clinical trial paradigm","volume":"12","author":"James","year":"2015","journal-title":"Nature Reviews. Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jhep.2012.07.028","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study","volume":"57","author":"Koehler","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/jgh.12428","article-title":"Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies","volume":"29","author":"Li","year":"2014","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD013157.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.3748\/wjg.v21.i22.7008","article-title":"Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis","volume":"21","author":"Li","year":"2015","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0362|cit362","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011640.pub2","article-title":"Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)","author":"Lombardi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Digestive and Liver Disease"},{"issue":"474","key":"10.1002\/14651858.CD013157.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons","volume":"101","author":"Lu","year":"2006","journal-title":"Journal of the American Statistical Association"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cct.2018.11.003","article-title":"European Paediatric Non-Alcoholic Fatty Liver Disease registry (EU-PNAFLD): design and rationale","volume":"75","author":"Mann","year":"2018","journal-title":"Contemporary Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"issue":"9128","key":"10.1002\/14651858.CD013157.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"Journal of Dairy Science"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0369|cit369","unstructured":"Fatty liver www.ncbi.nlm.nih.gov\/mesh\/68005234"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research","volume":"21","author":"Newell","year":"1992","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013157.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","article-title":"Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012","volume":"50","author":"Nishioji","year":"2015","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0372|cit372","unstructured":"OmniPage 18.0 Nuance 2011"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3109\/00365521.2014.934911","article-title":"Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD","volume":"49","author":"Onnerhag","year":"2014","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0375|cit375","unstructured":"Members of OpenBUGS project management group OpenBUGS 2014"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0376|cit376","unstructured":"Patient-reported Outcomes | What We Do | SF Health Surveys | SF-36v2 Health Survey, 2018 www.qualitymetric.com\/health-surveys\/the-sf-36v2-health-survey\/"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD013157.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2005.04086.x","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults","volume":"21","author":"Park","year":"2006","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v4.i12.327","article-title":"Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment","volume":"4","author":"Paschos","year":"2012","journal-title":"World Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0380|cit380","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical research edition)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jclinepi.2017.12.008","article-title":"The cohort multiple randomized controlled trial design was found to be highly susceptible to low statistical power and internal validity biases","volume":"95","author":"Reeves","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"C1066","DOI":"10.1136\/bmj.c1066","article-title":"Rethinking pragmatic randomised controlled trials: introducing the \"cohort multiple randomised controlled trial\" design","volume":"340","author":"Relton","year":"2010","journal-title":"BMJ (Clinical research edition)"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/jcp.2006.044891","article-title":"A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease","volume":"60","author":"Riley","year":"2007","journal-title":"Journal of Clinical Pathology"},{"issue":"22","key":"10.1002\/14651858.CD013157.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"35","key":"10.1002\/14651858.CD013157.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES Meta-Epidemiologic Study","volume":"187","author":"Savovi\u0107","year":"2018","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0392|cit392","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JT Deeks JJ Glasziou P Chapter 12. Interpreting results and drawing conclusions. In: Higgins JT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.2517-6161.1993.tb01921.x","article-title":"Bayesian interval estimates which are also confidence intervals","volume":"55","author":"Severini","year":"1993","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"9","key":"10.1002\/14651858.CD013157.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/apt.12944","article-title":"Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from The Third National Health and Nutrition Examination Survey","volume":"40","author":"Shen","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD013157.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1210\/jc.2016-2353","article-title":"Exercise training reduces liver fat and increases rates of VLDL clearance but not VLDL production in NAFLD","volume":"101","author":"Shojaee-Moradie","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013157.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1002\/14651858.CD013157.pub2-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0398|cit398","unstructured":"Stata\/SE StataCorp LLC 2016"},{"issue":"5","key":"10.1002\/14651858.CD013157.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1002\/14651858.CD013157.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Valkenhoef","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3904\/kjim.2015.253","article-title":"Diagnostic value of alcoholic liver disease (ALD)\/nonalcoholic fatty liver disease (NAFLD) index combined with gamma-glutamyl transferase in differentiating ALD and NAFLD","volume":"31","author":"Wang","year":"2016","journal-title":"Korean Journal of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013157.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"7644","key":"10.1002\/14651858.CD013157.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical research edition)"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nunez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013157.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/EDE.0000000000000435","article-title":"Brief report: staged-informed consent in the cohort multiple randomized controlled trial design","volume":"27","author":"Young-Afat","year":"2016","journal-title":"Epidemiology (Cambridge, Mass)"},{"issue":"8","key":"10.1002\/14651858.CD013157.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013157.pub2-BIB0407|cit407","unstructured":"Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis Cochrane Database of Systematic Reviews 2018 10 10.1002\/14651858.CD013157"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T11:18:10Z","timestamp":1673349490000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013157.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":407,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013157.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}